Telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development, a recent article reads. SS Innovations International (NASDAQ: SSII) is central to that shift, with its founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, positioning the company in an increasingly relevant part of the surgical robotics market. Dr. Srivastava told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness.
The company reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations. Its installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. These figures underscore the growing adoption of the system and its expanding role in remote surgery. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets.
The growing interest in telerobotic surgery is putting SS Innovations and Dr. Srivastava in the spotlight. A recent MedTech Dive report, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery while the company awaits key regulatory decisions that could open the U.S. and European markets.
Regulatory clearances in the U.S. and Europe would significantly expand the addressable market for SS Innovations, allowing it to compete more directly with established surgical robotics players. The company’s progress in telesurgery, including long-distance cardiac procedures, demonstrates the clinical viability of remote operations and could influence how regulators and healthcare providers approach telemedicine in surgery. As healthcare systems seek to extend specialized surgical expertise to underserved regions, telerobotic surgery offers a potential solution to geographic barriers. SS Innovations’ expanding global footprint and procedural volume suggest that remote surgery is gaining traction, and its pursuit of FDA and CE mark approvals will be critical in determining whether it can translate its international experience into broader adoption in major markets.
Investors and industry observers can follow the latest news and updates relating to SSII in the company’s newsroom at https://ibn.fm/SSII. The evolving regulatory landscape for telerobotic surgery, combined with SS Innovations’ clinical milestones, positions the company at the intersection of technological innovation and market expansion. As remote procedures gain ground worldwide, SS Innovations’ ability to secure approvals and scale its telesurgery programs will shape its competitive standing in the global surgical robotics market.
